Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Baxter
Moodys
Boehringer Ingelheim
Medtronic

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR PORTIA-21


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Portia-21

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00117273 ↗ A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens Completed Duramed Research Phase 3 2005-06-01 This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
NCT00196365 ↗ A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain Completed Duramed Research Phase 3 2005-01-01 This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 26 weeks of treatment. The overall study duration will be approximately 9 months. Patients will be required to record menstrual pain in a daily diary.
NCT01170390 ↗ Oral Contraceptives and Body Mass Index Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 4 2009-09-01 The main hypothesis for this study is that increased Body Mass Index (BMI) alters oral contraceptive metabolism in a manner which results in decreased effectiveness in obese women.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Portia-21

Condition Name

Condition Name for Portia-21
Intervention Trials
Contraceptive Usage 1
Dysmenorrhea 1
Healthy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Portia-21
Intervention Trials
Pituitary Diseases 1
HIV Infections 1
Body Weight 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Portia-21

Trials by Country

Trials by Country for Portia-21
Location Trials
United States 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Portia-21
Location Trials
Texas 2
Oregon 2
Florida 2
California 1
Colorado 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Portia-21

Clinical Trial Phase

Clinical Trial Phase for Portia-21
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Portia-21
Clinical Trial Phase Trials
Completed 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Portia-21

Sponsor Name

Sponsor Name for Portia-21
Sponsor Trials
Duramed Research 2
Pfizer 2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Portia-21
Sponsor Trials
Industry 5
Other 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Merck
McKesson
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.